Type 2 DM as initial therapy to improve glycemic control when diet & exercise alone do not provide adequate glycemic control. Type 2 DM as adjunct to diet & exercise to improve glycemic control in patients who can not be controlled with metformin or sitagliptin alone or in patients already being treated with combination of sitagliptin & metformin. As part of triple combination therapy with a sulfonylurea or with a PPARY agonist (ie, thiazolidinediones) as an adjunct to diet & exercise in patients with type 2 DM inadequately controlled with any 2 of 3 agents: Metformin, sitagliptin or a sulfonylurea alone or a PPARY agonist alone. Type 2 DM as an adjunct to diet & exercise to improve glycemic control in combination with insulin; sitagliptin & metformin.

This is not a substitute for consulting your doctor. Seek professional advice if you are experiencing any illness or symptoms.

Individualized dosing. Initial therapy: Starting dose 50 mg/500 mg bid. May be titrated with sitagliptin 50mg + metformin 1,000 mg bid. Patient inadequately controlled on metformin monotherapy Sitagliptin 50 mg bid + metformin already taken. Patient inadequately controlled on sitagliptin monotherapy 50 mg/ 500 mg tab bid. May be titrated up to 50 mg/1,000 mg tab bid. Patient inadequately controlled on dual combination therapy with any 2 of the following 3 antihyperglycemic agents: Sitagliptin, metformin or a PPARY agonist (ie, thiazolidinediones) Usual starting dose: 50 mg bid (100 mg total daily dose). In determining the starting dose of the metformin component, the patient's level of glycemic control & current dose (if any) of metformin should be considered.

Should be taken with food.